March 19, 2024 09:00 AM EDTUpdated 11:51 AM
R&D

High­ly-await­ed PhI­II study of Gates-backed tu­ber­cu­lo­sis vac­cine un­der­way

Ryan Cross

Senior Science Correspondent

A large study of an ex­per­i­men­tal vac­cine for the world’s biggest in­fec­tious dis­ease has fi­nal­ly kicked off in South Africa.
The Bill & Melin­da Gates …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times